Rubella

Rubella and Congenital Rubella Syndrome

Generalities
Agent	Rubella virus, genus Rubullovirus, family Togaviridae
Incubation period	14-17 days (range 14-21 days)
Period of transmissibility	- 7 days before rash and 4 days after rash onset - From congenital rubella: infants shed the virus for several months after birth
Reservoir	Humans
Modes of transmission	- Person-to-person: direct contact with droplets - Infants with Congenital Rubella Syndrome shed large quantities of virus in their pharyngeal secretions and urine. - Materno-foetal transmission: 90% of infants born to women infected with rubella during the 1st trimester. The risk of transmission is 10-20% by the 16th week, and rare after the 20th week.
Clinical presentation	- Febril maculo-papular rash - Complications: thrombocytopenia (1/3000), post-infectious encephalitis (1/6000), rarely chronic arthritis - Congenital Rubella Syndrome: Congenital malformation as deafness, cataracts, microphtalmia, congenital glaucoma, pigmentary retinopathy, nystagmus, microcephaly, meningo-encephalitis, mental retardation, patent ductus arteious, atrial or ventricular septal defects, other congenital heart disease, purpura, hepatosplenomegaly, jaundice, radiolucent bone disease
Resources
Case definitions	- MOPH circular no 12 (2013): Acquired Rubella - MOPH circular no 45 (2007): Congenital Rubella Syndrome
Forms	- Rash reporting form - CRS reporting form - Rash investigation form - CRS investigation form
Data	- Rubella 2021 - Rubella 2020 - Rubella 2019 - Rubella 2018 - Rubella 2017 - Rubella 2016 - Rubella 2015

...

191

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
R01AD09	TABUNEX	G	Mometasone furoate - 0.05%	0.05%	Spray	419,279 L.L
D07AD01	DERMOVATE	B	Clobetasol (propionate) - 0.5mg/g	0.05% w/w	Cream	245,923 L.L
D07AD01	DERMOVATE	B	Clobetasol (propionate) - 0.5mg/g	0.05% w/w	Cream	245,923 L.L
D07AD01	DERMOVATE	B	Clobetasol (propionate) - 0.5mg/g	0.05% w/w	Ointment	245,923 L.L
D07AD01	DERMOVATE	B	Clobetasol (propionate) - 0.5mg/g	0.05% w/w	Ointment	245,923 L.L
C01AA05	LANOXIN PG	B	Digoxin - 0.05mg/ml	0.05mg/ml	Elixir	307,740 L.L
G03CA03	OESTRODOSE	B	Estradiol (17 bêta estradiol anhydre) - 0.06%	0.06%	Gel	642,357 L.L
B05XA01	CHLORURE DE POTASSIUM PROAMP	G	Potassium chloride - 0.0746g/ml	0.0746g/ml	Injectable concentrated solution	1,252,461 L.L
D07AB02	LOCOID	B	Hydrocortisone butyrate - 1mg/g	0.1%	Cream	215,015 L.L
D07AB02	LOCOID	B	Hydrocortisone butyrate - 1mg/g	0.1%	Cream	215,015 L.L
D07AB02	LOCOID	B	Hydrocortisone butyrate - 0.1%	0.1%	Lipocream	221,734 L.L
D07AB02	LOCOID	B	Hydrocortisone butyrate - 0.1%	0.1%	Lipocream	221,734 L.L
D07AB02	LOCOID CRELO 0.1%	B	Hydrocortisone butyrate - 1mg/g	0.1%	Emulsion	177,387 L.L
D07AB02	LOCOID CRELO 0.1%	B	Hydrocortisone butyrate - 1mg/g	0.1%	Emulsion	177,387 L.L
D07AB02	LOCOID	B	Hydrocortisone butyrate - 0.1%	0.1%	Lotion	201,576 L.L
D07AB02	LOCOID	B	Hydrocortisone butyrate - 0.1%	0.1%	Lotion	201,576 L.L
D07AC01	BETNOVATE	B	Betamethasone - 0.1%	0.1%	Solution	235,172 L.L
D07AC13	ELICA	G	Mometasone furoate - 1mg/g	0.1%	Cream	341,336 L.L
D07AC13	ELISONE	G	Mometasone furoate - 0.1%	0.1%	Cream	249,955 L.L
D07AC13	ELISONE	G	Mometasone furoate - 0.1%	0.1%	Cream	435,405 L.L
D07AC13	METASONE	G	Mometasone furoate - 0.1%	0.1%	Cream	335,321 L.L
D07AC13	XEMADERM	G	Mometasone furoate - 0.1%	0.1%	Cream	335,961 L.L
D07AC13	ELICA	G	Mometasone furoate micronized - 1mg/g	0.1%	Ointment	399,121 L.L
D07AC13	ELOCOM	B	Mometasone furoate - 1mg/g	0.1%	Lotion	282,207 L.L
D07AC13	KONEX	G	Mometasone furoate - 0.1%	0.1%	Solution	385,683 L.L
D07AC13	METASONE	G	Mometasone furoate - 0.1%	0.1%	Lotion	239,332 L.L
D07AC14	PRENIDERM	G	Methylprednisolone aceponate - 0.1%	0.1%	Cream	312,283 L.L
S01GX09	PATANOL	B	Olopatadine (HCl) - 0.1%	0.1%	Drops solution	873,498 L.L
S01GX09	CONJYCLEAR	G	Olopatadine (HCl) - 0.1%	0.1%	Drops solution	510,660 L.L
S01GX09	OLOHISTINE	G	Olopatadine (HCl) - 0.1%	0.1%	Solution	522,755 L.L

...

191